Status:
COMPLETED
Pilot Study to Evaluate Escitalopram in Obsessive-compulsive Disorder
Lead Sponsor:
Duke University
Collaborating Sponsors:
Forest Laboratories
Conditions:
OCD
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This study will determine the safety and effectiveness of escitalopram (Lexapro)in treating obsessive-compulsive disorder (OCD) symptoms.
Detailed Description
OCD is a chronic and disabling disorder for which Selective Serotonin Reuptake Inhibitor(SSRI) drugs can be effective. The purpose of this study is to evaluate the effects of an SSRI, escitalopram, in...
Eligibility Criteria
Inclusion
- Diagnosis of OCD
- A minimum score of 16 on the Yale Brown Obsessive-Compulsive Scale (YBOCS) at both the screening and baseline visits
Exclusion
- Lifetime history of psychosis or cognitive dysfunction due to a general medical condition or substance use
- A primary diagnosis of another Axis I psychiatric disorder
- Alcohol or other substance abuse or dependence within the last 6 months
- Unstable medical condition
- Clinically significant laboratory abnormality
- Failure of a previous 10-week trial of citalopram of at least 40 mg/day or escitalopram 20 mg/day
- Active suicidality
- History of violent behavior in the past year or current risk of serious violence
- A history of sensitivity to citalopram or escitalopram
- Use of other investigational drugs within 30 days of baseline or other psychotropic drugs or herbs within 14 days of baseline (28 days for fluoxetine)
- Need for concurrent psychotherapeutic intervention
- Pregnant or lactating females.
Key Trial Info
Start Date :
October 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2009
Estimated Enrollment :
14 Patients enrolled
Trial Details
Trial ID
NCT00215137
Start Date
October 1 2004
End Date
March 1 2009
Last Update
July 23 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Duke University Medical Center
Durham, North Carolina, United States, 27710